Search research articles
Contact Us
Filters
Showing results (261-270 of 418) with videos related to
Page
of 42
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
May 9, 2024
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma
Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Plos One
|
July 2, 2014
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics
Dennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations
Martin H Voss, Cinta Hierro, Rebecca S Heist, et al.
Nature
|
July 6, 2012
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman, Teppei Morikawa, Kevin Shee, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy
Andrew D Knight, Emily J Robitschek, Jia-Ren Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 29, 2012
Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment
Valentina Nardi, Peter M Sadow, Dejan Juric, et al.
The Oncologist
|
March 19, 2017
Academic Cancer Center Phase I Program Development
Arthur E Frankel, Keith T Flaherty, George J Weiner, et al.
The Lancet. Oncology
|
June 9, 2017
Dabrafenib plus trametinib in patients with BRAF<sup>V600</sup>-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A Davies, Philippe Saiag, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 10, 2021
Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]
Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
Page
of 42
Search research articles
Search
Showing results (261-270 of 418) with videos related to
Sort By:
Page
of 42
European Journal of Cancer (Oxford, England : 1990)
|
May 9, 2024
COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma
Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, et al.
Plos One
|
July 2, 2014
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics
Dennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, et al.
Nature Medicine
|
October 6, 2020
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2019
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations
Martin H Voss, Cinta Hierro, Rebecca S Heist, et al.
Nature
|
July 6, 2012
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman, Teppei Morikawa, Kevin Shee, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy
Andrew D Knight, Emily J Robitschek, Jia-Ren Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 29, 2012
Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment
Valentina Nardi, Peter M Sadow, Dejan Juric, et al.
The Oncologist
|
March 19, 2017
Academic Cancer Center Phase I Program Development
Arthur E Frankel, Keith T Flaherty, George J Weiner, et al.
The Lancet. Oncology
|
June 9, 2017
Dabrafenib plus trametinib in patients with BRAF<sup>V600</sup>-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A Davies, Philippe Saiag, Caroline Robert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 10, 2021
Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]
Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
Page
of 42